Page last updated: 2024-12-09

(3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolyl)-(3-methyl-1-pyrazolyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a very specific chemical compound, **(3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolyl)-(3-methyl-1-pyrazolyl)methanone**. This compound is actually quite complex and has a rather long and complicated name. To understand its importance, we need to break it down:

**Understanding the Structure:**

* **Thieno[2,3-c]pyrazole:** This is a fused ring system containing both a thiophene ring (a 5-membered ring with a sulfur atom) and a pyrazole ring (a 5-membered ring with two nitrogen atoms).
* **3-Methyl-1-phenyl-5-thieno[2,3-c]pyrazolyl:** This describes a specific derivative of the thieno[2,3-c]pyrazole ring system. It has a methyl group (CH3) at the 3rd position, a phenyl group (C6H5) at the 1st position, and the thieno[2,3-c]pyrazole ring is attached to the rest of the molecule at the 5th position.
* **(3-methyl-1-pyrazolyl)methanone:** This refers to another pyrazole ring (3-methyl-1-pyrazolyl) connected to a carbonyl group (C=O) which in turn connects to the thieno[2,3-c]pyrazole ring.

**Why is it Important for Research?**

While the specific importance of **(3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolyl)-(3-methyl-1-pyrazolyl)methanone** is not widely known, it's likely that researchers are interested in it due to its unique structure and potential applications in:

* **Medicinal Chemistry:** The presence of both pyrazole and thiophene rings, along with the ketone functionality, makes it a potential candidate for drug discovery. These rings are often found in molecules with biological activity.
* **Materials Science:** The combination of heterocyclic rings and carbonyl groups could influence the compound's properties, making it potentially useful in developing new materials with specific functionalities.
* **Organic Synthesis:** This complex molecule can be used as a starting material or intermediate in the synthesis of other novel compounds with potential applications.

**To learn more about its specific importance, you would need to look at:**

* **Published Research:** Search for scientific publications that mention this compound specifically.
* **Patent Databases:** Check patent databases to see if any patents have been filed related to this molecule.
* **Research Groups:** Contact research groups working in the relevant fields (medicinal chemistry, materials science, organic chemistry) to see if they have any ongoing projects involving this compound.

**Remember, the name alone does not tell us the full story. Its significance can only be truly understood by delving into the scientific literature and research surrounding it.**

Cross-References

ID SourceID
PubMed CID765480
CHEMBL ID1323617
CHEBI ID107114

Synonyms (17)

Synonym
(3-methyl-1-phenyl-1h-thieno[2,3-c]pyrazol-5-yl)-(3-methyl-pyrazol-1-yl)-methanone
smr000146323
MLS000552808 ,
OPREA1_251565
OPREA1_695894
CHEBI:107114
(3-methyl-1-phenylthieno[2,3-c]pyrazol-5-yl)-(3-methylpyrazol-1-yl)methanone
AKOS005616216
(3-methyl-1-phenyl-1h-thieno[2,3-c]pyrazol-5-yl)(3-methyl-1h-pyrazol-1-yl)methanone
STK762498
HMS2294E11
CHEMBL1323617
(3-methyl-1-phenyl-5-thieno[2,3-c]pyrazolyl)-(3-methyl-1-pyrazolyl)methanone
Q27185142
3-methyl-1-{3-methyl-1-phenyl-1h-thieno[2,3-c]pyrazole-5-carbonyl}-1h-pyrazole
sr-01000432098
SR-01000432098-1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
pyrazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency44.66840.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.16230.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.16230.125919.1169125.8920AID2549
LuciferasePhotinus pyralis (common eastern firefly)Potency6.74560.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency12.589314.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency31.62280.100020.879379.4328AID588456
ClpPBacillus subtilisPotency3.54811.995322.673039.8107AID651965
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.95260.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.23115.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency0.23115.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.23115.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency1.12200.100028.9256213.3130AID588591
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.22 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]